Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Trial Program Offers Six Free Infusions Of Kogenate FS

This article was originally published in The Pink Sheet Daily

Executive Summary

“The Kogenate FS Experience Program” includes an opportunity for hemophilia A patients in the U.S. to sample support programs and services, in addition to free treatment.

You may also be interested in...



Bayer Kogenate FS Free Trial Program Fails To Include Labeling, FDA Says

The CBER ad division letter cites the promotional materials for lack of risk information and failure to provide adequate direction for use.

Bayer Kogenate FS Free Trial Program Fails To Include Labeling, FDA Says

The CBER ad division letter cites the promotional materials for lack of risk information and failure to provide adequate direction for use.

Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off

Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel